Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.49 |
| ▸ | BHMT | Q93088 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382091 | 1.00 | CDC25B (0.50) | CDC25BSLC15A1BHMTALDH1A1MAPK1 | |
| Methylamine SCHEMBL27674682 | 0.96 | CDC25B (0.47) | CDC25BSLC15A1BHMTALDH1A1MAPK1 | |
| SCHEMBL2679262 | 0.86 | CDC25B (0.52) | CDC25BSLC15A1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2679263 | 0.86 | CDC25B (0.52) | CDC25BSLC15A1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL124385 | 0.81 | SLC15A1 (0.55) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 | |
| SCHEMBL4850398 | 0.81 | SLC15A1 (0.55) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 | |
| SCHEMBL432780 | 0.81 | SLC15A1 (0.55) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 | |
| SCHEMBL10996772 | 0.80 | IDO1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 | |
| SCHEMBL10996770 | 0.80 | IDO1 (0.56) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 | |
| Hydrochloric Acid SCHEMBL29398213 | 0.80 | SLC15A1 (0.53) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101481325-A | Basic amino acid metalloproteinase inhibitor and use thereof | UNIV SHANDONG (CN) | 2009-07-15 | — | — | CN | claimed |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023161881-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| CN-1300303-A | Enzyme inhibitors | PROCTER & GAMBLE (US) | 2001-06-20 | — | — | CN | disclosed |
| EP-1079821-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999059570-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| CN-1027640-C | Process for producing novel trifluoromethyl ketone substituted peptide derivatives | ICI AMERICA INC (US) | 1995-02-15 | — | — | CN | disclosed |
| CN-1019803-B | 1,3, the preparation method of 4-thiadiazoles derivative | FISONS PLC (GB) | 1992-12-30 | — | — | CN | disclosed |
| CN-87101916-A | The preparation method of pharmaceutically active compounds | — | 1988-08-24 | — | — | CN | disclosed |
| CN-86101066-A | Process for producing novel trifluoromethyl ketone substituted peptide derivatives | — | 1986-11-05 | — | — | CN | disclosed |
| CN-85102340-A | The method for preparing immunostimulant acyl tripeptides | — | 1986-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | CDC25B 4245/4885SLC15A1 1805/4885BHMT 53/4885 |
| US-20250057958-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | CDC25B 1380/4885SLC15A1 1852/4885BHMT 3019/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | CDC25B 4245/4885SLC15A1 1805/4885BHMT 53/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | CDC25B 4245/4885SLC15A1 1805/4885BHMT 53/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | CDC25B 4245/4885SLC15A1 1805/4885BHMT 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.